BioNTech’s €500 Million Efficiency Drive Fuels a Pipeline Bet the Market Has Yet to Price In

BioNTech is executing a multi-front strategy that pits aggressive cost-cutting against a deepening oncology pipeline — yet the stock, hovering near €76, has shrugged off both the savings plan and fresh clinical data. The Mainz-based biotech is laying off staff, closing legacy vaccine sites, and pouring resources into a drug development machine it hopes will deliver ten cancer approvals by 2030. For now, investors remain fixated on the shrinking COVID revenue line and the long wait for Phase 3 results.

The most tangible near-term move is the restructuring of BioNTech’s manufacturing footprint. The former CureVac headquarters in Tübingen will shut by the end of 2026, eliminating roughly two-thirds of the jobs there. Severance offers are slated for September. Sites in Idar-Oberstein and Marburg are to be vacated by the end of 2027, and the Singapore facility follows in the first quarter of that same year. BioNTech is exploring partial or full sales of all four locations. The goal: €500 million in annual savings by 2029, with a large chunk of that freed capital redirected into the oncology pipeline. From 2026 onward, Pfizer will handle all COVID vaccine supply, unwinding the pandemic-era infrastructure. Around 1,860 positions are affected across the restructuring.

While the company dials down vaccine operations, its most advanced oncology candidate — BNT323 (Trastuzumab Pamirtecan) — is closing in on a regulatory milestone. BioNTech and partner DualityBio plan to file a marketing application with the FDA in 2026, pending agency feedback. The antibody-drug conjugate targets HER2-expressing endometrial cancer. In a mid-stage trial, the confirmed overall response rate across all HER2 levels reached 47.9%. Among patients who had already received an immune checkpoint inhibitor, that figure rose to 49.3%, with median progression-free survival of 8.1 months. The drug’s strongest showing came in the IHC 3+ subgroup, where more than 70% of patients responded. Crucially, BNT323 also demonstrated activity at lower HER2 expression levels — 33.9% in IHC 1+ and 40.4% in IHC 2+ — an area where currently no HER2-directed therapy is approved. That could provide a clear differentiation from AstraZeneca and Daiichi Sankyo’s Enhertu, which holds accelerated FDA approval only for IHC 3+.

Should investors sell immediately? Or is it worth buying BioNTech?

Alongside BNT323, BioNTech presented additional data at the ASCO annual meeting in Chicago. The ROSETTA Lung-02 study showed encouraging antitumor activity for pumitamig combined with chemotherapy in first-line non-small cell lung cancer. It is the third global dataset to show consistent results for that combination, following data in small-cell lung cancer and triple-negative breast cancer. Separately, gotistobart — a CTLA-4-targeting candidate — demonstrated durable tumor activity and clinically relevant survival data in platinum-resistant ovarian cancer without chemotherapy. Despite the breadth of these readouts, the stock barely moved. The pattern suggests the market will only reward hard proof from the ongoing Phase 3 studies.

The financial backdrop underscores the transition. First-quarter 2026 revenue fell to €118 million from €183 million a year earlier. BioNTech held its full-year guidance of €2.0?billion to €2.3?billion in COVID vaccine sales. An up-to-€1?billion share buyback program is running, and liquidity stood at roughly €17?billion at the end of 2025 (or €16.8?billion as of March 2026). The cash pile provides ample runway for the pipeline, but the revenue decline highlights the urgency of delivering a new commercial product.

Analyst sentiment is split along the timeline. UBS upgraded BioNTech to “Buy” ahead of ASCO, raising its price target from $117 to $135, betting on the late-stage oncology pipeline. Bernstein’s Jeffrey Walch initiated with “Market Perform” and a $96 target, arguing that upside is limited until the key clinical milestones materialize. The stock closed Friday at €76.65, down 7.1% year-to-date and 19.5% over twelve months. Technically, it remains under pressure: the relative strength index is 38, the price sits more than 6% below its 50-day moving average, and the gap to the 200-day average is 10.8%. The January high of €105.80 looks distant.

For the coming weeks, macro data will drive near-term sentiment — US inflation figures on June 10–11 and the Fed decision on June 16–17. Company-specific catalysts are thinner on the ground until the FDA filing for BNT323 crystallizes. That application, if successful, would give BioNTech a foothold in a niche where no HER2-directed therapy yet exists, potentially altering the market’s calculus. Until then, the stock remains a bet on a future that the present-quarter numbers are not yet ready to endorse.

Ad

BioNTech Stock: New Analysis - 8 June

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69500679 |